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Background
Allergic rhinitis (AR) patients often present with a predo-
minant symptom. Nasal congestion and ocular symptoms
have the greatest negative impact on patients’ quality of
life [1]. Our aim was to assess the efficacy of MP29-02*
(a novel intranasal formulation of azelastine hydrochloride
[AZE] and fluticasone propionate [FP] in an advanced
delivery system) in seasonal AR (SAR) patients presenting
with nasal congestion or ocular itch predominantly com-
pared to AZE, FP or placebo (PLA) nasal sprays.
Methods
610 patients (≥12 yrs old) with moderate/severe SAR
were randomized into a double-blind, PLA-controlled,
14-day, parallel-group trial to MP29-02*, AZE FP or
PLA nasal sprays (all 1 spray/nostril bid [total daily
doses: AZE 548μg; FP 200μg]). Patients were categorized
as nasal congestion- or ocular itch-predominant (for
those patients with baseline rTOSS ≥ 8) according to
maximal symptom scores at baseline. Targeted symptom
reduction was assessed for each predominant symptom
over the entire 14 day period and on each day.
Results
Congestion-predominant MP29-02*-patients experienced
3 times the congestion relief of FP-patients (p=0.0018) and
5 times the relief provided by AZE (p=0.0001). AZE and
FP did not significantly differ from PLA. Superior conges-
tion relief afforded by MP29-02* in these patients was evi-
dent from Day 2 vs FP (p=0.0155), AZE (p=0.0032) and
PLA (p=0.0010) and sustained for 14 days. The level of
relief achieved by MP29-02* patients on Day 2 (-0.90) was
not achieved before Day 9 by either FP or AZE patients.
Ocular itch predominant MP29-02*-patients experienced
4 times the ocular itch relief as FP-patients (p=0.0026) and
twice the relief provided by AZE (p=0.0551). FP did not
provide additional ocular itch relief over the placebo
response. The level of ocular itch relief achieved by MP29-
02* patients on Day 2 (-0.93) was not achieved before Day
9 by FP patients or before Day 4 by AZE patients.
Conclusion
Unlike currently available first line therapy, MP29-02*
effectively and rapidly reduced nasal congestion and
ocular itch in patients suffering predominantly from
these symptoms. MP29-02*’s rapidity and effectiveness
in relieving predominant congestion and ocular itch
could lead to a reduction in the need for concomitant
decongestants and eye drops, respectively and further
supports the position of MP29-02* as the drug of choice
for the treatment of AR.
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